FibroBiologics, Inc.
FBLGHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeFibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company carries a $6.7M market cap, placing it firmly in the micro-cap category. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
Market Cap
$6.7M
Beta
1.74
P/E (TTM)
—
P/E (Fwd)
-0.29
EPS (TTM)
$-4.64
EPS (Fwd)
$-3.25
ROE
-660.1%
ROA
-95.8%
Cash
$3.5M
Total Debt
$1.5M
Free CF
-$8.4M
52W Change
-89.1%
Annual Financials
Cash vs Debt
Where FBLG stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, FBLG finished 32.37% below its 150-day moving average ($1.39) and 64.12% below its 200-day moving average ($2.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FBLG overbought or oversold?
At the October 20, 2026 close, FBLG's RSI(14) was 19.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
FibroBiologics, Inc. holds $3.5M in cash against $1.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$8.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -660.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
FibroBiologics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, FBLG has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence FibroBiologics, Inc.'s trajectory.